Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dermatology

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

Pfizer’s Litfulo recommended by NICE as first treatment for severe alopecia areata

Up to 14,000 patients living with the autoimmune disease could benefit from NICE’s decision

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

- PMLiVE

Medicxi forms Alys Pharma with six dermatology-focused companies with $100m

Alys will keep its component companies separate to focus on their platforms

- PMLiVE

Almirall and Microsoft partner to accelerate digital transformation in medical dermatology

The alliance is aimed at advancing the research of solutions for dermatological diseases

- PMLiVE

Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

Approximately 17,000 cases of melanoma are diagnosed in the UK every year

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

- PMLiVE

Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

Dermatological diseases are estimated to affect 1.8 billion people worldwide

- PMLiVE

Almirall and Absci announce $650m AI dermatological drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in long-term chronic hand eczema study

There are currently no topical treatments specifically approved for moderate-to-severe CHE

- PMLiVE

World Psoriasis Day: Almirall highlights impact of disease on patient well-being

Almost 77% of patients believe that psoriasis negatively affects their daily life and well-being

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links